Acadia Pharmaceuticals
12830 El Camino Real, Suite 400
San Diego
California
92130
United States
Tel: (858) 558-2871
Website: https://www.acadia-pharm.com/
520 articles with Acadia Pharmaceuticals
-
Acadia Pharmaceuticals announced the approval of Daybue (trofinetide) as the first and only drug to treat Rett Syndrome, a rare, neurodegenerative disorder affecting primarily girls.
-
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
3/11/2023
Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved DAYBUE™ for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.
-
FDA Action Alert: Roche and Acadia
3/6/2023
The FDA's Oncologic Drugs Advisory Committee will meet March 9 to discuss Roche's sBLA for Polivy in first-line DLBCL, while Acadia awaits potential approval of the first therapy for Rett Syndrome. -
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview
2/27/2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2022.
-
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
2/14/2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2022 financial results on Monday, February 27, 2023, after the close of the U.S. financial markets.
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 13, 2023
2/13/2023
Acadia Pharmaceuticals Inc. announced that on February 10, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 310,065 shares of common stock and 97,251 restricted stock units to 19 new employees under Acadia’s 2023 Inducement Plan.
-
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
1/9/2023
Acadia Pharmaceuticals Inc. announced the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development.
-
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
1/3/2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID® (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups.
-
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
12/21/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session.
-
Acadia Pharmaceuticals to Participate at Upcoming November 2022 Investor Conferences
11/8/2022
Acadia Pharmaceuticals Inc. announced that it will participate at the following upcoming investor conferences.
-
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
11/2/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2022.
-
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
10/27/2022
Acadia Pharmaceuticals Inc. announced that its President, Srdjan Stankovic, M.D., M.S.P.H., who is responsible for R&D, and Medical and Scientific functions, will retire at the end of the year.
-
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
10/20/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the U.S. financial markets.
-
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
10/13/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors.
-
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
10/4/2022
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed.
-
The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.
-
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
9/12/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome.
-
Acadia Pharmaceuticals to Present at Upcoming September 2022 Investor Conferences
9/1/2022
Acadia Pharmaceuticals Inc. announced that it will participate at the following upcoming investor conferences.
-
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
8/8/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.